1. Home
  2. FVCB vs CABA Comparison

FVCB vs CABA Comparison

Compare FVCB & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FVCBankcorp Inc.

FVCB

FVCBankcorp Inc.

HOLD

Current Price

$15.64

Market Cap

267.9M

Sector

Finance

ML Signal

HOLD

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

HOLD

Current Price

$3.31

Market Cap

319.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FVCB
CABA
Founded
2007
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
267.9M
319.6M
IPO Year
2018
2019

Fundamental Metrics

Financial Performance
Metric
FVCB
CABA
Price
$15.64
$3.31
Analyst Decision
Buy
Strong Buy
Analyst Count
1
6
Target Price
$18.00
$14.50
AVG Volume (30 Days)
97.4K
2.0M
Earning Date
05-01-2026
05-14-2026
Dividend Yield
1.54%
N/A
EPS Growth
47.56
10.26
EPS
1.21
N/A
Revenue
$1,781,000.00
N/A
Revenue This Year
$13.83
N/A
Revenue Next Year
$7.45
N/A
P/E Ratio
$12.85
N/A
Revenue Growth
13.87
N/A
52 Week Low
$9.95
$1.11
52 Week High
$16.35
$3.78

Technical Indicators

Market Signals
Indicator
FVCB
CABA
Relative Strength Index (RSI) 63.63 57.85
Support Level $15.40 $2.07
Resistance Level $16.35 $3.34
Average True Range (ATR) 0.37 0.21
MACD 0.04 0.05
Stochastic Oscillator 75.77 76.22

Price Performance

Historical Comparison
FVCB
CABA

About FVCB FVCBankcorp Inc.

FVCBankcorp Inc is a registered bank holding company. It operates through the sole subsidiary, which is a community-oriented, locally-owned, and managed commercial bank. It offers commercial banking services to small and medium-sized businesses, professionals, non-profit organizations and associations, and investors. It also provides retail banking services to accommodate the individual needs of both corporate customers as well as the communities it serves. The bank provides other facilities such as online banking, mobile banking, remote deposit service, and lending products, among others. Its primary source of revenue is the net interest income.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

Share on Social Networks: